Early symptom relief and satisfaction with perfluorohexyloctane ophthalmic solution in dry eye disease: a prospective, multicenter study
CLOSE
MENU

Early symptom relief and satisfaction with perfluorohexyloctane ophthalmic solution in dry eye disease: a prospective, multicenter study


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Early symptom relief and satisfaction with perfluorohexyloctane ophthalmic solution in dry eye disease: a prospective, multicenter study


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Summary

PURPOSE: Perfluorohexyloctane ophthalmic solution (PFHO; MIEBO) is indicated for the treatment of signs and symptoms of dry eye disease (DED). This study evaluated patient perceptions and satisfaction early in treatment with PFHO.

METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06309953) enrolled adults with history of DED for ≥6 months, tear film breakup time (TFBUT) ≤5 sec, Schirmer I test (without anesthesia) score ≥5 mm, Meibomian gland dysfunction (MGD) score ≥3 (range, 0-15), and total corneal fluorescein staining (tCFS) score ≥4 and ≤11 (range, 0-15). PFHO was instilled in both eyes QID for 14 days. Patients completed early outcome surveys on days 1 (baseline), 3, 7, and 14 clinic visits, which assessed DED symptom severity (overall and 8 symptoms) and treatment satisfaction (visual analog scale [0-100]). Primary endpoint was mean change from baseline (CFB) in overall DED symptom severity at Day 7.

RESULTS: 99 patients were enrolled (mean age, 61.3 years; 85.9% females). At baseline, mean scores (both eyes) were: TFBUT, 3.6 sec; Schirmer I test, 14.2 mm; MGD score, 8.3; and tCFS, 5.2. Mean CFB in overall DED symptom severity was statistically significant at Day 7 (baseline: 72.1; Day 7: 27.8; CFB: -44.5 [61.7% reduction]; P<0.0001) and at all follow-up visits (P<0.0001). Mean CFB was also statistically significant (P<0.0001) at all follow-up times for severity of all 8 symptoms (eye dryness, burning/stinging, eye itching, light sensitivity, eye pain, eye tiredness, eye irritation, and blurred vision). Median rating of treatment satisfaction was 83.0 at Day 3, 86.0 at Day 7, and 90.0 at Day 14.

CONCLUSIONS: Early in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptoms severity. Treatment satisfaction with PFHO was high.

For More Information:

Get Support

Contact Us

Contact a
Representative

Find My Local Rep link-out icon

Submit a
Medical Inquiry

Complete the Form